课题基金 / 基金详情

Biomarker Discovery and Validation in Parkinson's Disease

Biomarker Discovery and Validation in Parkinson's Disease
帕金森病生物标志物的发现和验证
批准号:
9269667
负责人:
Ted M. Dawson
金额:
$66.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2020-03-31

项目摘要

项目成果

Ted M. Dawson的其他基金

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
ABSTRACT Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder after Alzheimer's disease. Although PD is associated with Lewy body formation in the substantia nigra and other regions of the brain, the pathologic and metabolic alterations occurring during the onset and progression of PD have not been clearly defined. Despite a critical need for a reliable diagnostic marker for PD, there is currently no such biomarker that can be used accurately in clinical practice for establishing a definitive diagnosis of PD. The difficulty of identifying reliable biomarkers can be attributed to the variability of clinical samples, low abundance of proteins that are involved in PD pathogenesis and the lack of reproducibility in validating biomarker candidates. To overcome these limitations, we propose use of a large cerebrospinal fluid (CSF) cohort with greater statistical power for true discovery and deep proteome analysis to discover PD biomarkers that are involved in PD pathogenesis, but are present at low abundance. In addition, multiplexed sample analysis by isobaric tandem mass tagging (TMT) with a common reference for data normalization will ensure robust analytical precision of quantitative proteomic data for discovery from a larger set of samples. Moreover, additional proteomic analysis of substantia nigra will be used to select those biomarkers that show differential expression in CSF as well as substantia nigra. These discovery platforms will use a bioinformatics approach to select the most plausible candidates for targeted validation studies followed by an intensive validation of the discovered biomarker candidates. To achieve these goals, we propose three aims: Specific Aim 1: To discover proteins that are differentially expressed in patients with Parkinson's disease. We plan to carry out a quantitative proteomic analysis of CSF and substantia nigra samples from patients with PD and from controls by employing TMT-based multiplexing technology. With this approach, we expect to obtain a more comprehensive coverage of a larger number of proteins quantified across the analyzed samples. Specific Aim 2: To prioritize candidates based on an integrative analysis of alterations in CSF and substantia nigra. By integrating the expression changes in CSF and substantia nigra with a network approach that takes advantage of the known biological pathways that have been described in PD, our approach should be able to select reliable PD biomarker candidates for validation by targeted PRM experiments. Specific Aim 3: To validate candidate protein biomarkers in a larger cohort using targeted parallel reaction monitoring (PRM) mass spectrometry using CSF samples from a PD cohort at Johns Hopkins. Biomarkers that are selected by selection algorithms based on these PRM experiments will finally be confirmed with blinded PDBP CSF samples. Through the approaches outlined above, we expect to discover and validate reliable PD biomarkers in a reproducible fashion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BIOMARKER DISCOVERY AND VALIDATION IN PSP
  • 批准号:
    9750090
  • 项目类别:
  • 资助金额:
    $94.4万
  • 财政年份:
    2018
  • 负责人:
    Ted M. Dawson
  • 依托单位:
Administrative Core
  • 批准号:
    8882841
  • 项目类别:
  • 资助金额:
    $19.44万
  • 财政年份:
    2014
  • 负责人:
    Ted M. Dawson
  • 依托单位:
Biology of Parkin and It's Role in Parkinson's Disease
  • 批准号:
    8882845
  • 项目类别:
  • 资助金额:
    $41.31万
  • 财政年份:
    2014
  • 负责人:
    Ted M. Dawson
  • 依托单位:
Biology of Parkin and Its Role in Parkinson's Disease
  • 批准号:
    8540519
  • 项目类别:
  • 资助金额:
    $12.15万
  • 财政年份:
    2012
  • 负责人:
    Ted M. Dawson
  • 依托单位:
海外基金